Anavex Life Sciences Corporation (AVXL)

May 09, 2025

Anavex Life Sciences Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView

May 09, 2025

May 09, 2025

Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey

May 09, 2025

May 06, 2025

Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX

May 06, 2025

May 06, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus

May 06, 2025

May 06, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times

May 06, 2025

May 06, 2025

Anavex Life Sciences Corp. to Announce Second Fiscal Quarter Financial Results on May 13, 2025 - Nasdaq

May 06, 2025

May 06, 2025

Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan

May 06, 2025

May 04, 2025

Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

May 04, 2025

May 04, 2025

Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World

May 04, 2025

May 02, 2025

Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News

May 02, 2025

May 02, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World

May 02, 2025

May 01, 2025

Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com

May 01, 2025

May 01, 2025

Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com

May 01, 2025

May 01, 2025

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times

May 01, 2025

May 01, 2025

Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com

May 01, 2025

Apr 30, 2025

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus

Apr 30, 2025

Apr 30, 2025

Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan

Apr 30, 2025

Apr 30, 2025

Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 30, 2025

Apr 30, 2025

Anavex Life Sciences Corp. to Present at The Citizens Life Sciences Conference in New York, May 2025 - Nasdaq

Apr 30, 2025

Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025

Apr 26, 2025

Lost Money on Anavex Life Sciences Corp.(AVXL)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - ACCESS Newswire

Apr 26, 2025

Apr 24, 2025

Anavex Life Sciences Corporation’s Market Journey: Closing Strong at 9.31, Up 1.09 - DWinneX

Apr 24, 2025

Apr 24, 2025

Buying Buzz: Anavex Life Sciences Corporation [AVXL] Director Donhauser Peter D.O. purchases 2,835 shares of the company – Knox Daily - knoxdaily.com

Apr 24, 2025

Apr 23, 2025

AVXL overperforms with a 5.14 increase in share price - uspostnews.com

Apr 23, 2025

Apr 23, 2025

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - The Manila Times

Apr 23, 2025

Apr 23, 2025

Harvard-Trained Alzheimer's Pioneer With 35,000-Patient Database Strengthens Anavex's Scientific Team - Stock Titan

Apr 23, 2025

Apr 21, 2025

Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance

Apr 21, 2025

Apr 21, 2025

Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer’s Data ... By GuruFocus - Investing.com Canada

Apr 21, 2025

Apr 21, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by LPL Financial LLC - Defense World

Apr 21, 2025

Apr 21, 2025

Anavex Life Sciences Presents Novel Alzheimer Treatment Research at International Conference in Abu Dhabi - Nasdaq

Apr 21, 2025

Apr 21, 2025

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East - TradingView

Apr 21, 2025

Apr 21, 2025

Breakthrough Alzheimer's Treatment Shows Novel Mechanism: Key Phase IIb/III Trial Results Unveiled - Stock Titan

Apr 21, 2025

Apr 20, 2025

Geode Capital Management LLC Has $20.14 Million Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 20, 2025

Apr 19, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Holdings Raised by Alliancebernstein L.P. - Defense World

Apr 19, 2025

Apr 13, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences LawsuitAVXL - ACCESS Newswire

Apr 13, 2025

Apr 13, 2025

Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN

Apr 13, 2025

Apr 13, 2025

Wellington Management Group LLP Makes New $1.70 Million Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 13, 2025

Apr 13, 2025

Raymond James Financial Inc. Acquires Shares of 15,584 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 13, 2025

Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 10,160 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 12, 2025

Apr 12, 2025

Vanguard Group Inc. Sells 59,727 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 12, 2025

Apr 10, 2025

Corebridge Financial Inc. Trims Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 10, 2025

Apr 09, 2025

Four-Year Data on New Drug for Early AD Positive - streetwisereports.com

Apr 09, 2025

Apr 08, 2025

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe - streetwisereports.com

Apr 08, 2025

Apr 08, 2025

Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright - Defense World

Apr 08, 2025

Apr 08, 2025

Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World

Apr 08, 2025

Apr 07, 2025

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years - Benzinga

Apr 07, 2025

Apr 05, 2025

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease - The Manila Times

Apr 05, 2025

Apr 05, 2025

Breakthrough: New Alzheimer's Drug Cuts Cognitive Decline Over 4 Years in Clinical Trial - Stock Titan

Apr 05, 2025

Apr 05, 2025

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Apr 05, 2025

Apr 02, 2025

Class Action Filed Against Anavex Life Sciences Corporation (AVXL)May 13, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Apr 02, 2025

Apr 02, 2025

Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class ActionAVXL - ACCESS Newswire

Apr 02, 2025

Apr 01, 2025

AVXL’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 01, 2025

Apr 01, 2025

Commonwealth Equity Services LLC Buys 7,285 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 01, 2025

Apr 01, 2025

Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at HC Wainwright - Defense World

Apr 01, 2025

Mar 31, 2025

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025

Mar 31, 2025

Anavex Showcases Breakthrough CNS Therapies: CEO Details Pipeline at Major Healthcare Conference - Stock Titan

Mar 31, 2025